|
Year
|
Title
|
Authors
|
Publication
|
|
2020
|
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
|
Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, Shaw BE, Muffly LS
|
Blood Advances 4(6):983-992
|
|
2020
|
Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes.
|
Cusatis RN, Tecca HR, D'Souza A, Shaw BE, Flynn KE
|
Cancer
|
|
2020
|
Higher total body irradiation dose-intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation: Flu/2Gy TBI vs Flu/4Gy TBI in NHL.
|
Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT
|
Biol Blood Marrow Transplant
|
|
2020
|
Clonal Hematopoiesis in related allogeneic transplant donors: Implications for screening and management.
|
Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, Seftel MD, Shaw BE
|
Biol Blood Marrow Transplant
|
|
2020
|
Generalized additive modeling of cost trajectories from healthcare claims data: Costs of treating privately-insured patients with acute myeloid leukemia in the United States 2004-2014.
|
Mau L-W, Preussler JM, Burns LJ, Leppke S, Majhail NS, Meyer CL, Mupfudze T, Saber W, Steinert P, Vanness DJ
|
PharmacoEconomics
|
|
2020
|
Incidence, risk factors for and outcomes of transplant‐associated thrombotic microangiopathy.
|
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M
|
Br J Haematol
|
|
2020
|
Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research.
|
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar A, Yoshimi A, Wirk B, Shaw B, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy SM, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W
|
Biol Blood Marrow Transplant 26(3):553-561
|
|
2020
|
Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation
|
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG
|
Biol Blood Marrow Transplant 26(3):606-611
|
|
2020
|
Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR study.
|
DeFilipp Z, Ancheta R, Liu Y, Hu Z-H, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus HM, Olsson R, Cahn J-Y, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W
|
Biol Blood Marrow Transplant 26(3):472-479
|
|
2020
|
Direct adjusted survival and cumulative incidence curves for observational studies.
|
Hu Z-H, Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(3):538-543
|
|
2020
|
Weighty choices: Selecting optimal G-CSF doses for stem cell mobilization to optimize yield.
|
Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR
|
Blood Advances 4(4):706-716
|
|
2020
|
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
|
Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS
|
Blood Advances 4(4):750-754
|
|
2020
|
Collection of peripheral blood progenitor cells in one day is associated with decreased donor toxicity compared to two days in unrelated donors.
|
Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredseon C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugure M, Warkentin P, Wingard JR
|
Biol Blood Marrow Transplant
|
|
2020
|
Analysis of Whole CDR3 TCR Repertoire After Hematopoietic Stem Cell Transplantation in Two Clinical Cohorts
|
Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, RangarajanK K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH
|
Biol Blood Marrow Transplant
|
|
2020
|
The role of donor lymphocyte infusion (DLI) in post hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era.
|
Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Chakrabarty JH, Saber W
|
Biol Blood Marrow Transplant
|
|
2020
|
Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
|
Jagadeesh D, Majhail N, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M
|
Cancer
|
|
2020
|
Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
|
Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales M-A, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang M-J, Gluckman E, Montoto S, Eapen M
|
J Clin Oncol
|
|
2020
|
Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia.
|
Savage SA, Viard M, O'hUigin C, Zhou W, Yeager M, Li SA, Wang T, Ramsuran V, Vince N, Vogt A, Hicks B, Burdett L, Chung C, Dean M, de Andrade KC, Freedman ND, Berndt SI, Rothman N, Lan Q, Cerhan JR, Slager SL, Zhang Y, Teras LR, Haagenson M, Chanock SJ, Spellman SR, Wang Y, Willis A, Askar M, Lee SJ, Carrington M, Gadalla SM
|
Am J Hum Genet 106(2):264-271
|
|
2020
|
Comprehensive prognostication in critically ill pediatric hematopoietic cell transplant patients: Results from merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.
|
Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC
|
Biol Blood Marrow Transplant 26(2):333-342
|
|
2020
|
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: Young HLA-matched unrelated or haploidentical donor?
|
Perales M-A, Tomlinson B, Zhang M-J, St. Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M
|
Haematologica 105(2):407-413
|
|
2020
|
Rapid donor identification improves survival in high-risk first-remission patients with acute myeloid leukemia.
|
Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow M, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer R-L, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR
|
JCO Oncol Pract
|
|
2020
|
Priorities for improving outcomes for non-malignant blood diseases: A report from the Blood and Marrow Transplant Clinical Trials Network.
|
Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N
|
Biol Blood Marrow Transplant
|
|
2020
|
Population frequency of Fanconi pathway gene variants and their association with survival after hematopoietic cell transplant for severe aplastic anemia.
|
McReynolds LJ, Wang Y, Thompson AS, Ballew BJ, Kim J, Alter BP, Hicks B, Zhu B, Jones K, Spellman SR, Wang T, Lee SJ, Savage SA, Gadalla S
|
Biol Blood Marrow Transplant
|
|
2020
|
Pre‐transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia.
|
Wang Y, McReynolds LJ, Dagnall C, Katki HA, Spellman SR, Wang T, Hicks B, Freedman ND, Jones K, Lee SJ, Savage SA, Gadalla SM
|
Br J Haematol 188(2):309-316
|
|
2020
|
Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation.
|
Wong WH, Bhatt S, Trinkaus K, Pusic I, Elliott K, Mahajan N, Wan F, Switzer GE, Confer DL, DiPersio J, Pulsipher MA, Shah NN, Sees J, Bystry A, Blundell JR, Shaw BE, Druley TE
|
Sci Transl Med 12(526):1-9
|
|
2020
|
Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?
|
Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M
|
Biol Blood Marrow Transplant
|
|
2020
|
Health care reimbursement, service utilization, and financial responsibility among Medicare beneficiaries with multiple myeloma receiving autologous hematopoietic cell transplantation in inpatient and outpatient settings.
|
Dunavin N, Mau L-W, Meyer CL, Divine C, Leppke S, D'Souza A, Denzen E, Saber W, Burns LJ, Ganguly S
|
Biol Blood Marrow Transplant
|
|
2020
|
Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant.
|
Dandoy CE, Kim S, Chen M, Ahn K-W, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales M-A, Lindemans CA, Komanduri KV, Riches ML
|
JAMA Netw Open 3(1):e1918668
|
|
2020
|
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: The BMT CTN 1501 trial.
|
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML
|
Blood 135(2):97-107
|
|
2020
|
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
|
Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL
|
Biol Blood Marrow Transplant 26(1):e7-e15
|
|
2020
|
Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: A retrospective cohort study.
|
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P
|
Lancet Haematol 7(1):e50-e60
|
|
2020
|
Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky.
|
Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):1-3
|
|
2020
|
Causal inference in randomized clinical trials.
|
Zheng C, Dai R, Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):4-8
|
